Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models. - Wikidata - wikimedia - TriplyDB

Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models.

Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models.

http://www.wikidata.org/entity/Q37538738

about

Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models.

http://www.wikidata.org/entity/Q37538738

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 31 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Comparative In Vivo Efficacies ...... umoniae Lung Infection Models.

@en

Comparative In Vivo Efficacies ...... umoniae Lung Infection Models.

@nl

type

label

Comparative In Vivo Efficacies ...... umoniae Lung Infection Models.

@en

Comparative In Vivo Efficacies ...... umoniae Lung Infection Models.

@nl

prefLabel

Comparative In Vivo Efficacies ...... umoniae Lung Infection Models.

@en

Comparative In Vivo Efficacies ...... umoniae Lung Infection Models.

@nl

P1433

Q37538738-B46E90AF-8C6C-4CE8-B426-2F9AD6191F57

P1476

Q37538738-BD6974F3-D80E-4B53-8F12-B04DE6749A77

P2093

Q37538738-8FC411B2-6D1F-438E-8861-8080BFA2C51D

Q37538738-B33CB1BA-E0C9-4D02-B737-F568D7EC57F2

P2860

Q37538738-1D75524E-B7C3-4387-AFD4-7F3A79FD1E5D

Q37538738-1D9824FA-6DAB-41E2-BAD3-792DB58CA6D0

Q37538738-22DDF98C-7A21-4C4D-B0AB-551E8D73DD71

Q37538738-2E5AE477-F022-47BC-93C0-1E0082550B44

Q37538738-339CDB7B-076E-4D0D-B7EE-0CE3EF4B20EA

Q37538738-4D6FE506-4C4A-4118-B90A-F0039550C326

Q37538738-58039427-0877-4162-8BD8-2776D5BC950A

Q37538738-5D657EE0-4F00-491E-9F81-E5C8E50E0338

Q37538738-6307FB7C-957F-40D1-B984-7C4F8AAD1FDD

Q37538738-73244E15-820A-4E07-8456-867FD2EC70A8

P31

Q37538738-BA9E739B-08A5-44A9-B723-2ED804BE4CB6

P356

Q37538738-2CA4AAC2-2183-4C5D-9EFB-BE43407BA721

P407

Q37538738-EB641B96-C131-4619-95A3-F19E3EE7FDD5

P433

Q37538738-CD72DD48-4AAD-4607-ABA6-F2938F8410A1

P478

Q37538738-E9A1BA3A-3EBF-423D-B534-0987BF7664C8

P577

Q37538738-B7AAA289-C23D-411E-BC02-00F3E7E8C3BA

P698

Q37538738-45FA0FE7-216E-41B8-8D51-902CD40AEF24

P932

Q37538738-031923F0-6277-4E91-9CEB-D04CE01BBA0E

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Comparative In Vivo Efficacies ...... umoniae Lung Infection Models.

@en

P2093

David P Nicolau

http://www.w3.org/2001/XMLSchema#string

Kamilia Abdelraouf

http://www.w3.org/2001/XMLSchema#string

P2860

Innate immune defense against pneumococcal pneumonia requires pulmonary complement component C3.

Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus

Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.

In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent

In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.

Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections

Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model

Susceptibility trends including emergence of linezolid resistance among coagulase-negative staphylococci and meticillin-resistant Staphylococcus aureus from invasive infections.

Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model.

Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers.

P31

scholarly article

P356

10.1128/AAC.01957-16

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27799200

http://www.w3.org/2001/XMLSchema#string

P932

5192146

http://www.w3.org/2001/XMLSchema#string